Hemoglobinuria

(redirected from PNH)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

hemoglobinuria

[‚hē·mə‚glō·bə′nu̇r·ē·ə]
(medicine)
A pathological condition in which the urine contains hemoglobin.

Hemoglobinuria

 

the presence of hemoglobin in urine. It usually is a result of the intravascular decomposition of red blood cells following the transfusion of incompatible blood, the effect of some chemical and biological poisons and drugs that cannot be tolerated or of any of several causative agents of infections, extensive injuries, and so on.

References in periodicals archive ?
All patients had PNH diagnosed by flow cytometry, and 61% had begun eculizumab therapy before conception.
Currently, severe cases of PNH are treated with eculizumab (Soliris), however due to the cost of the drug, widely considered to be one of the most expensive drug in the world, the majority of patients are monitored and treated with symptomatic and supportive approaches such as: folic acid (folate) supplements, anticoagulation therapy, steroids, growth factors, blood transfusions and bone marrow transplants.
PNH functions not only with the funds that are donated by individuals and businesses but also by working with other nonprofits to satisfy the requirements of certain grants.
Alexion is the global leader in complement inhibition and has developed and markets Soliris([R]) (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation.
We are now looking to conclude the sale of our remaining Admiral territories and we are delighted to be working with PNH and hope to finalise our divestment from the sports licensing sector shortly, allowing us to utilise these funds to further build our diagnostics business.
SHEPHERD and TRIUMPH Phase III clinical trials, which also showed significant reductions in hemolysis, anemia, transfusion dependence, and fatigue among patients with PNH in the U.
Alexion acquired exclusive world-wide rights to FLAER, a highly sensitive diagnostic test for PNH.
There are no therapies specifically available for the treatment of PNH in Europe.
The TRIUMPH trial included 87 PNH patients and the SHEPHERD trial has enrolled 97 PNH patients.
Other severe complications of PNH include deficiencies of other blood cell types and thrombosis, both of which can cause death.
PNH accounts for a large share of the eardrop market in Nashville, Tenn.